These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 30175625

  • 21. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J.
    Clin Infect Dis; 2016 Dec 01; 63(11):1470-1474. PubMed ID: 27578820
    [Abstract] [Full Text] [Related]

  • 22. Translational regenerative medicine research: essential to discovery and outcome.
    Mason C, Dunnill P.
    Regen Med; 2007 May 01; 2(3):227-9. PubMed ID: 17511558
    [No Abstract] [Full Text] [Related]

  • 23. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J.
    Clin Infect Dis; 2017 Oct 15; 65(8):1378-1382. PubMed ID: 29017240
    [Abstract] [Full Text] [Related]

  • 24. Countries mull over incentives for developing antibiotics.
    Anderson T.
    Lancet; 2016 May 07; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract] [Full Text] [Related]

  • 25. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS, Fernando K, Allerton C, Jansen KU, Vincent MS, Dolsten M.
    Drug Discov Today; 2021 Feb 07; 26(2):308-314. PubMed ID: 33129994
    [Abstract] [Full Text] [Related]

  • 26. In the midst of the antimicrobial discovery conundrum: an overview.
    Tomaras AP, Dunman PM.
    Curr Opin Microbiol; 2015 Oct 07; 27():103-7. PubMed ID: 26356257
    [No Abstract] [Full Text] [Related]

  • 27. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI, Revel L, Rosa E, Cruces E.
    Drug News Perspect; 2009 Oct 07; 22(1):39-51. PubMed ID: 19209298
    [Abstract] [Full Text] [Related]

  • 28. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J.
    BMJ; 2016 May 19; 353():i2863. PubMed ID: 27198868
    [No Abstract] [Full Text] [Related]

  • 29. Antibiotics in late clinical development.
    Fernandes P, Martens E.
    Biochem Pharmacol; 2017 Jun 01; 133():152-163. PubMed ID: 27687641
    [Abstract] [Full Text] [Related]

  • 30. China spurs pharma innovation.
    Hughes B.
    Nat Rev Drug Discov; 2010 Aug 01; 9(8):581-2. PubMed ID: 20671751
    [No Abstract] [Full Text] [Related]

  • 31. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R, Green S.
    J Antimicrob Chemother; 2015 May 01; 70(5):1281-4. PubMed ID: 25634991
    [Abstract] [Full Text] [Related]

  • 32. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH, Mohr JF.
    Expert Rev Anti Infect Ther; 2017 May 01; 15(5):425-433. PubMed ID: 28306360
    [Abstract] [Full Text] [Related]

  • 33. The abandonment of antibacterials: why and wherefore?
    Shlaes DM.
    Curr Opin Pharmacol; 2003 Oct 01; 3(5):470-3. PubMed ID: 14559090
    [Abstract] [Full Text] [Related]

  • 34. The antibacterial drugs market.
    Kresse H, Belsey MJ, Rovini H.
    Nat Rev Drug Discov; 2007 Jan 01; 6(1):19-20. PubMed ID: 17269159
    [No Abstract] [Full Text] [Related]

  • 35. Academia and industry: allocating credit for discovery and development of new therapies.
    Flier JS.
    J Clin Invest; 2019 May 20; 129(6):2172-2174. PubMed ID: 31107243
    [No Abstract] [Full Text] [Related]

  • 36. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K, Rex JH.
    Transl Res; 2020 Jun 20; 220():182-190. PubMed ID: 32165059
    [Abstract] [Full Text] [Related]

  • 37. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL, Renwick MJ, Kelly R, Mossialos E.
    J Antibiot (Tokyo); 2017 Dec 20; 70(12):1087-1096. PubMed ID: 29089600
    [Abstract] [Full Text] [Related]

  • 38. Costly Genes.
    Karayiorgou M.
    PLoS Genet; 2020 Aug 20; 16(8):e1008889. PubMed ID: 32817613
    [No Abstract] [Full Text] [Related]

  • 39. Overcoming the current deadlock in antibiotic research.
    Schäberle TF, Hack IM.
    Trends Microbiol; 2014 Apr 20; 22(4):165-7. PubMed ID: 24698433
    [Abstract] [Full Text] [Related]

  • 40. Incentives aim to boost antibiotic development.
    Roberts JP.
    Nat Biotechnol; 2012 Aug 20; 30(8):735. PubMed ID: 22871701
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.